Leonteq Securities AG Makes New Investment in Illumina, Inc. $ILMN

Posted by on May 23rd, 2026

Leonteq Securities AG purchased a new position in Illumina, Inc. (NASDAQ:ILMN – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 4,937 shares of the life sciences company’s stock, valued at approximately $648,000.

Several other hedge funds have also bought and sold shares of ILMN. Capital World Investors lifted its stake in Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares in the last quarter. Nordea Investment Management AB lifted its stake in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Illumina in the 4th quarter worth about $73,532,000. State Street Corp increased its holdings in shares of Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after buying an additional 382,520 shares during the last quarter. Finally, Duquesne Family Office LLC bought a new stake in shares of Illumina in the 2nd quarter worth about $28,682,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on ILMN shares. Robert W. Baird set a $137.00 target price on shares of Illumina in a report on Friday, February 6th. Barclays boosted their target price on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Guggenheim boosted their target price on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Canaccord Genuity Group reduced their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a report on Friday, May 1st. Finally, Citigroup boosted their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Illumina presently has a consensus rating of “Hold” and an average target price of $137.75.

Check Out Our Latest Stock Analysis on Illumina

Insider Activity

In related news, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 225,067 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director owned 3,604,441 shares in the company, valued at $524,626,387.55. The trade was a 5.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 330,160 shares of company stock worth $48,028,308 over the last quarter. 2.90% of the stock is currently owned by insiders.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $144.41 on Friday. The company has a market capitalization of $21.85 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 2.40 and a beta of 1.42. Illumina, Inc. has a 12 month low of $78.55 and a 12 month high of $155.53. The firm’s 50-day moving average is $130.45 and its 200 day moving average is $130.91. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.2 EPS for the current year.

Illumina Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Read More

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.